, Volume 36, Issue 4, pp 445–447 | Cite as

N″-cyano-N-4-pyridyl-N′-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): A new, potent vasodilator

  • E. Arrigoni-Martelli
  • C. Kaergaard Nielsen
  • U. Bang Olsen
  • H. J. Petersen


N″-cyano-N-4-pyridyl-N′-1,2,2-trimethylpropylguanidine, monohydrate (P 1134) is a new agent which induces a marked and sustained hypotensive response in normotensive and renal, neurogenic, and spontaneously hypertensive rats, as well as in normotensive and renal hypertensive dogs. The overall potency of this compound is 2–3 times greater than that of hydralazine. The fall of blood pressure is accompanied by an increase in heart rate and cardiac output and a decrease in total peripheral resistance. The hypotensive effect appears to be due primarily to a direct relaxant effect on vascular smooth muscle.


Cardiac Output Plasma Renin Activity Hydralazine Mean Arterial Blood Pressure Hypotensive Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 2.
    J. Koch-Weser, Arch. intern. Med.133, 1017 (1974).CrossRefPubMedGoogle Scholar
  2. 3.
    H.J. Petersen, German Patent offenleg. 2557438, 1976.Google Scholar
  3. 4.
    H.J. Petersen, C. Kaergaard-Nielsen and E. Arrigoni-Martelli, J. med. Chem.21, 773 (1978).CrossRefPubMedGoogle Scholar
  4. 5.
    A.W. Ganz, Am. J. Cardiol.29, 241 (1972).CrossRefPubMedGoogle Scholar
  5. 6.
    E. Haber, T. Koerner, L.B. Page and B. Kliman, J. clin. Endocr. Metab.29, 1349 (1979).CrossRefGoogle Scholar
  6. 7.
    A. Grollmann, Proc. Soc. exp. Biol. Med.57, 102 (1944).CrossRefGoogle Scholar
  7. 8.
    H. Goldblatt, J. Lynch, R.F. Hanzan and W.W. Summerville, J. exp. Med.59, 347 (1934).CrossRefPubMedPubMedCentralGoogle Scholar
  8. 9.
    A.H. Krieger, Circulation Res.15, 511 (1964).CrossRefPubMedGoogle Scholar
  9. 10.
    S. Mellander and R. Johansson, Pharmac. Rev.20, 117 (1968).Google Scholar
  10. 11.
    H. Brunner, P.R. Hedwall and M. Meier, Br. J. Pharmac.30, 123 (1967).Google Scholar
  11. 12.
    A.A. Rubin, L. Zitowitz and L. Hausler, J. Pharmac. exp. Ther.140, 46 (1963).Google Scholar
  12. 13.
    H.J. Bein, F. Gross, J. Tripod and R. Meier, Schweiz. med. Wschr.83, 336 (1953).PubMedGoogle Scholar
  13. 14.
    F. Gross, J. Druey and R. Meier, Experientia6, 11 (1950).CrossRefGoogle Scholar
  14. 15.
    C. Carpi and L. Dorigotti Br. J. Pharmac.52, 459 (1974).Google Scholar
  15. 16.
    The (+)- and (−)-forms were obtained by fractionated crystallization of the D(−)- and (+)-tartrates, respectively, from 80% EtOH. [a]D20:+135° and −135° (c=1, EtOH).Google Scholar
  16. 17.
    T. Hilden, personal communication.Google Scholar

Copyright information

© Birkhäuser Verlag 1980

Authors and Affiliations

  • E. Arrigoni-Martelli
    • 1
  • C. Kaergaard Nielsen
    • 1
  • U. Bang Olsen
    • 1
  • H. J. Petersen
    • 1
  1. 1.Department of Pharmacology and Department of ChemistryLeo Pharmaceutical ProductsBallerupDenmark

Personalised recommendations